journal
Journals Seminars in Respiratory and Cr...

Seminars in Respiratory and Critical Care Medicine

https://read.qxmd.com/read/38740369/novel-therapeutic-approaches-in-connective-tissue-disease-associated-interstitial-lung-disease
#1
JOURNAL ARTICLE
Erica Mulcaire-Jones, Janelle Vu Pugashetti, Justin M Oldham, Dinesh Khanna
Connective tissue diseases (CTD) comprise a group of autoimmune diseases that can affect multiple organs in the body including the lungs. The most common form of pulmonary involvement is interstitial lung disease (ILD). CTD-associated ILD (CTD-ILD) can take one of several courses including nonprogressive, chronically progressive, or rapidly progressive. Chronically and rapidly progressive patterns are associated with increased mortality. Limited randomized controlled trial data are available for treatment of CTD-ILD, with most data coming from systemic sclerosis-related ILD...
May 13, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38714203/interstitial-lung-disease-associated-with-systemic-sclerosis
#2
JOURNAL ARTICLE
Valentine Mismetti, Salim Si-Mohamed, Vincent Cottin
Systemic sclerosis (SSc) is a rare autoimmune disease characterized by a tripod combining vasculopathy, fibrosis, and immune-mediated inflammatory processes. The prevalence of interstitial lung disease (ILD) in SSc varies according to the methods used to detect it, ranging from 25 to 95%. The fibrotic and vascular pulmonary manifestations of SSc, particularly ILD, are the main causes of morbidity and mortality, contributing to 35% of deaths. Although early trials were conducted with cyclophosphamide, more recent randomized controlled trials have been performed to assess the efficacy and tolerability of several medications, mostly mycophenolate, rituximab, tocilizumab, and nintedanib...
May 7, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38710221/review-of-pulmonary-manifestations-in-antisynthetase-syndrome
#3
JOURNAL ARTICLE
Mohammad I Ghanbar, Sonye K Danoff
Antisynthetase syndrome (ASyS) is now a widely recognized entity within the spectrum of idiopathic inflammatory myopathies. Initially described in patients with a triad of myositis, arthritis, and interstitial lung disease (ILD), its presentation can be diverse. Additional common symptoms experienced by patients with ASyS include Raynaud's phenomenon, mechanic's hand, and fever. Although there is a significant overlap with polymyositis and dermatomyositis, the key distinction lies in the presence of antisynthetase antibodies (ASAs)...
May 6, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38631369/diagnostic-approach-to-interstitial-lung-diseases-associated-with-connective-tissue-diseases
#4
JOURNAL ARTICLE
Ana C Zamora, Lewis J Wesselius, Michael B Gotway, Henry D Tazelaar, Alejandro Diaz-Arumir, Vivek Nagaraja
Interstitial lung disorders are a group of respiratory diseases characterized by interstitial compartment infiltration, varying degrees of infiltration, and fibrosis, with or without small airway involvement. Although some are idiopathic (e.g., idiopathic pulmonary fibrosis, idiopathic interstitial pneumonias, and sarcoidosis), the great majority have an underlying etiology, such as systemic autoimmune rheumatic disease (SARD, also called Connective Tissue Diseases or CTD), inhalational exposure to organic matter, medications, and rarely, genetic disorders...
April 17, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38626906/the-oral-lung-microbiome-axis-in-connective-tissue-disease-related-interstitial-lung-disease
#5
JOURNAL ARTICLE
Kale S Bongers, Angeline Massett, David N O'Dwyer
Connective tissue disease-related interstitial lung disease (CTD-ILD) is a frequent and serious complication of CTD, leading to high morbidity and mortality. Unfortunately, its pathogenesis remains poorly understood; however, one intriguing contributing factor may be the microbiome of the mouth and lungs. The oral microbiome, which is a major source of the lung microbiome through recurrent microaspiration, is altered in ILD patients. Moreover, in recent years, several lines of evidence suggest that changes in the oral and lung microbiota modulate the pulmonary immune response and thus may play a role in the pathogenesis of ILDs, including CTD-ILD...
April 16, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38621712/pulmonary-manifestations-of-sj%C3%A3-gren-s-disease
#6
JOURNAL ARTICLE
Louise Byrne, Cormac McCarthy, Aurelie Fabre, Nishant Gupta
Sjögren's disease (SjD) is a chronic, progressive autoimmune condition of exocrine and extraglandular tissues. It can present with isolated disease characterized by lymphocytic infiltration of salivary or lacrimal glands, but in approximately one-third of the patients, lymphocytic infiltration extends beyond exocrine glands to involve extraglandular organs such as the lungs. Pulmonary complications have been reported to occur between 9 and 27% of patients with SjD across studies. Respiratory manifestations occur on a spectrum of severity and include airways disease, interstitial lung disease, cystic lung disease, and lymphoma...
April 15, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38547917/pleural-diseases-in-connective-tissue-diseases
#7
JOURNAL ARTICLE
Hui Guo, Beenish Iqbal, Najib M Rahman
Connective tissue diseases (CTD) are heterogeneous, immune-mediated inflammatory disorders often presenting with multiorgan involvement. With the advent of high-resolution computed tomography, CTD-related pleuritis-pleural thickening and effusion-is now increasingly recognized early in the disease trajectory. The natural history of CTD-related pleural effusions varies from spontaneous resolution to progressive fibrothorax with ventilatory impairment. Treatment of the underlying CTD is necessary to manage the pleural disease...
March 28, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38547916/approach-to-pulmonary-nodules-in-connective-tissue-disease
#8
JOURNAL ARTICLE
Brian Gaffney, David J Murphy
The assessment of pulmonary nodules is a common and often challenging clinical scenario. This evaluation becomes even more complex in patients with connective tissue diseases (CTDs), as a range of disease-related factors must also be taken into account. These diseases are characterized by immune-mediated chronic inflammation, leading to tissue damage, collagen deposition, and subsequent organ dysfunction. A thorough examination of nodule features in these patients is required, incorporating anatomic and functional information, along with patient demographics, clinical factors, and disease-specific knowledge...
March 28, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38547915/systemic-lupus-erythematosus-related-lung-disease
#9
JOURNAL ARTICLE
Elisabeth Bendstrup, Evelyn Lynn, Anne Troldborg
Systemic Lupus Erythematosus (SLE) is a multifaceted, multisystem autoimmune disorder with diverse clinical expressions. While prevalence reports vary widely, pulmonary involvement accounts for significant morbidity and mortality in SLE. This comprehensive review explores the spectrum of pulmonary disease in SLE, including upper airway manifestations (e.g., laryngeal affection), lower airway conditions (e.g., bronchitis, bronchiolitis, bronchiectasis), parenchymal diseases (e.g., interstitial lung disease, acute lupus pneumonitis, diffuse alveolar hemorrhage), pleural diseases (e...
March 28, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38531379/pulmonary-manifestations-of-connective-tissue-diseases
#10
JOURNAL ARTICLE
Sarah Cullivan, Eleanor Cronin, Sean Gaine
Systemic sclerosis is a multisystem connective tissue disease that is associated with substantial morbidity and mortality. Visceral organ involvement is common in patients with systemic sclerosis and occurs independently of skin manifestations. Pulmonary hypertension (PH) is an important and prevalent complication of systemic sclerosis. The clinical classification of PH cohorts conditions with similar pathophysiological mechanisms into one of five groups. While patients with systemic sclerosis can manifest with a spectrum of pulmonary vascular disease, notable clinical groups include group 1 pulmonary arterial hypertension (PAH) associated with connective tissues disease, PAH with features of capillary/venous involvement, group 2 PH associated with left heart disease, and group 3 PH associated with interstitial lung disease...
March 26, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38499196/pulmonary-hypertension-in-connective-tissue-diseases-other-than-systemic-sclerosis
#11
JOURNAL ARTICLE
Brandon Budhram, Jason Weatherald, Marc Humbert
Pulmonary hypertension (PH) is a known complication of certain connective tissue diseases (CTDs), with systemic sclerosis (SSc) being the most common in the Western world. However, PH in association with non-SSc CTD such as systemic lupus erythematous, mixed connective tissue disease, and primary Sjögren's syndrome constitutes a distinct subset of patients with inherently different epidemiologic profiles, pathophysiologic mechanisms, clinical features, therapeutic options, and prognostic implications. The purpose of this review is to inform a practical approach for clinicians evaluating patients with non-SSc CTD-associated PH...
March 18, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38484788/overview-of-rheumatoid-arthritis-associated-interstitial-lung-disease-and-its-treatment
#12
JOURNAL ARTICLE
Janelle Vu Pugashetti, Joyce S Lee
Interstitial lung disease (ILD) is a common pulmonary complication of rheumatoid arthritis (RA), causing significant morbidity and mortality. Optimal treatment for RA-ILD is not yet well defined. Reliable prognostic indicators are largely byproducts of prior ILD progression, including low or decreasing forced vital capacity and extensive or worsening fibrosis on imaging. In the absence of validated tools to predict treatment response, decisions about whether to initiate or augment treatment are instead based on clinical judgment...
March 14, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38428839/new-guidelines-for-severe-community-acquired-pneumonia
#13
JOURNAL ARTICLE
Davide Calabretta, Ignacio Martìn-Loeches, Antoni Torres
In 2023, the new European guidelines on severe community-acquired pneumonia, providing clinical practice recommendations for the management of this life-threatening infection, characterized by a high burden of mortality, morbidity, and costs for the society. This review article aims to summarize the principal evidence related to eight different questions covered in the guidelines, by also highlighting the future perspectives for research activity.
March 1, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38768644/corrigendum-severe-community-acquired-pneumonia-noninvasive-mechanical-ventilation-intubation-and-hfnt
#14
JOURNAL ARTICLE
Miquel Ferrer, Gennaro De Pascale, Eloisa S Tanzarella, Massimo Antonelli
No abstract text is available yet for this article.
April 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38604188/severe-community-acquired-pneumonia-noninvasive-mechanical-ventilation-intubation-and-hfnt
#15
JOURNAL ARTICLE
Miquel Ferrer, Gennaro De Pascale, Eloisa S Tanzarella, Massimo Antonelli
Severe acute respiratory failure (ARF) is a major issue in patients with severe community-acquired pneumonia (CAP). Standard oxygen therapy is the first-line therapy for ARF in the less severe cases. However, respiratory supports may be delivered in more severe clinical condition. In cases with life-threatening ARF, invasive mechanical ventilation (IMV) will be required. Noninvasive strategies such as high-flow nasal therapy (HFNT) or noninvasive ventilation (NIV) by either face mask or helmet might cover the gap between standard oxygen and IMV...
April 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38604187/severe-community-acquired-pneumonia
#16
JOURNAL ARTICLE
Ignacio Martin-Loeches, Antoni Torres
No abstract text is available yet for this article.
April 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38395062/long-term-outcomes-in-severe-community-acquired-pneumonia
#17
REVIEW
Francesco Carella, Stefano Aliberti, Anna Stainer, Antonio Voza, Francesco Blasi
Community-acquired pneumonia (CAP) is globally one of the major causes of hospitalization and mortality. Severe CAP (sCAP) presents great challenges and need a comprehensive understanding of its long-term outcomes. Cardiovascular events and neurological impairment, due to persistent inflammation and hypoxemia, contribute to long-term outcomes in CAP, including mortality. Very few data are available in the specific population of sCAP. Multiple studies have reported variable 1-year mortality rates for patients with CAP up to 40...
April 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38266998/severe-community-acquired-pneumonia-in-immunocompromised-patients
#18
REVIEW
Dara Chean, Camille Windsor, Antoine Lafarge, Thibault Dupont, Sabrine Nakaa, Livia Whiting, Adrien Joseph, Virginie Lemiale, Elie Azoulay
Due to higher survival rates with good quality of life, related to new treatments in the fields of oncology, hematology, and transplantation, the number of immunocompromised patients is increasing. But these patients are at high risk of intensive care unit admission because of numerous complications. Acute respiratory failure due to severe community-acquired pneumonia is one of the leading causes of admission. In this setting, the need for invasive mechanical ventilation is up to 60%, associated with a high hospital mortality rate of around 40 to 50%...
April 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38330995/definition-epidemiology-and-pathogenesis-of-severe-community-acquired-pneumonia
#19
JOURNAL ARTICLE
Rodrigo Cavallazzi, Julio A Ramirez
The clinical presentation of community-acquired pneumonia (CAP) can vary widely among patients. While many individuals with mild symptoms can be managed as outpatients with excellent outcomes, there is a distinct subgroup of patients who present with severe CAP. In these cases, the mortality rate can reach approximately 25% within 30 days and even up to 50% within a year. It is crucial to focus attention on these patients who are at higher risk.Among the various definitions of severe CAP found in the literature, one commonly used criterion is the requirement for admission to intensive care unit...
February 8, 2024: Seminars in Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38301713/risk-of-multidrug-resistant-pathogens-in-severe-community-acquired-pneumonia
#20
JOURNAL ARTICLE
E Campaña-Duel, M Camprubí-Rimblas, A Areny-Balagueró, Sara Quero, A Artigas, A Ceccato
Severe community-acquired pneumonia (SCAP) is difficult to treat when caused by difficult-to-treat (DTR) pathogens because of limited treatment options and poorer clinical outcomes. Over time, several predictive scoring systems based on risk factors for infection with multidrug resistant pathogens have been developed. We reviewed the available tools for identifying DTR pathogens as the cause of SCAP, both predictive scoring systems and rapid diagnostic methods, to develop management strategies aimed at early identification of DTR pathogens, reducing broad-spectrum antibiotic use and improving clinical outcomes...
February 1, 2024: Seminars in Respiratory and Critical Care Medicine
journal
journal
31946
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.